Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 10/20 | 0.71 |
| ▸ | TP53 | P04637 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147929 | 0.91 | ANO1 (0.73) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4139730 | 0.89 | ANO1 (0.72) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL8289815 | 0.87 | ANO1 (0.68) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4144067 | 0.85 | TLR2 (0.64) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL20353855 | 0.84 | ANO1 (0.68) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4132150 | 0.84 | MAPT (0.73) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4135545 | 0.83 | ANO1 (0.67) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4149386 | 0.83 | MAPT (0.73) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4144292 | 0.83 | ANO1 (0.72) | ANO1TP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL4151223 | 0.83 | ANO1 (1.00) | ANO1TP53MAPTSMN1; SMN2ANO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | ANO1 3854/4885TP53 1/4885MAPT 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.